No Data
No Data
Raymond James Initiates Q32 Bio at Strong Buy With $90 Price Target
Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80
Express News | Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes
Q32 Bio Initiated at Overweight by Wells Fargo
Q32 Bio Analyst Ratings
No Data
No Data